US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dianthus Therapeutics Inc.

18.85

+0.28001.51%

Post-market: 18.850.00000.00%16:20 EDT

Volume:370.38K

Turnover:6.98M

Market Cap:606.22M

PE:-6.71

High:19.31

Open:19.00

Low:18.58

Close:18.57

Loading ...

Overview Company News Filings

Dianthus Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Simon Read

Dianthus Therapeutics Appoints Simon Read, Ph.d., to Board of Directors

THOMSON REUTERS

Press Release: Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

Dianthus Therapeutics Inc. Appoints Simon Read, Ph.D., to Board as Leon O. Moulder, Jr. Resigns

Dianthus Therapeutics Inc: Phase 2 Momentum Trial of Dnth103 in Multifocal Motor Neuropathy Ongoing; Top-Line Results Anticipated in 2H'26

THOMSON REUTERS

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Dianthus Therapeutics Inc expected to post a loss of 85 cents a share - Earnings Preview

Dianthus Therapeutics Completes Enrollment of Phase 2 Magic Trial of Dnth103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

THOMSON REUTERS

Dianthus Therapeutics Inc: Top-Line Results Anticipated This September

THOMSON REUTERS

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

Point72 Asset Management, L.p. Reports 5.9% Passive Stake in Dianthus Therapeutics as of April 10 - SEC Filing

THOMSON REUTERS

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position

Dianthus Therapeutics Inc: $357.0 Mln of Cash Provides Runway Into 2H'27

THOMSON REUTERS

Dianthus Therapeutics Inc - Q4 Shr Loss $0.81

THOMSON REUTERS

Dianthus Therapeutics Q4 EPS $(0.81) Beats $(0.85) Estimate, Sales $1.32M Beat $859.70K Estimate

Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, a Seasoned Commercial Leader, to Board of Directors

THOMSON REUTERS

Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?

Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/DNTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DNTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNTH\",,,,,undefined,":{"symbol":"DNTH","market":"US","secType":"STK","nameCN":"Dianthus Therapeutics Inc.","latestPrice":18.85,"timestamp":1749240000000,"preClose":18.57,"halted":0,"volume":370376,"hourTrading":{"tag":"盘后","latestPrice":18.85,"preClose":18.85,"latestTime":"16:20 EDT","volume":4192,"amount":79019.2,"timestamp":1749241200445},"delay":0,"floatShares":10988522,"shares":32159982,"eps":-2.810198,"marketStatus":"Market Closed","change":0.28,"latestTime":"06-06 16:00:00 EDT","open":19,"high":19.305,"low":18.58,"amount":6979092.6209,"amplitude":0.039041,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.810198,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":18.57,"postHourTrading":{"tag":"盘后","latestPrice":18.85,"preClose":18.85,"latestTime":"16:20 EDT","volume":4192,"amount":79019.2,"timestamp":1749241200445},"volumeRatio":1.7675957337753283,"impliedVol":0.2534,"impliedVolPercentile":0.0435},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNTH\",,,,,undefined,":{"symbol":"DNTH","floatShares":10988522,"roa":"-20.04%","roe":"-28.73%","lyrEps":-2.55056,"volumeRatio":1.7675957337753283,"shares":32159982,"dividePrice":0,"high":19.305,"amplitude":0.039041,"preClose":18.57,"low":18.58,"week52Low":13.365,"pbRate":"1.84","psRate":"92.92","week52High":32.27,"institutionHeld":0,"latestPrice":18.85,"eps":-2.810198,"divideRate":0,"volume":370376,"delay":0,"ttmEps":-2.810198,"open":19,"prevYearClose":21.8,"prevWeekClose":17.39,"prevMonthClose":17.39,"prevQuarterClose":18.14,"fiveDayClose":17.39,"twentyDayClose":20.62,"sixtyDayClose":21.9},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DNTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537927362","title":"Dianthus Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Simon Read","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927362","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927362?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:40","pubTimestamp":1747946429,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Simon Read as a beneficial owner in the role of Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL67sqY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2537924009","title":"Dianthus Therapeutics Appoints Simon Read, Ph.d., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924009","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924009?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:10","pubTimestamp":1747944600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nTUA46NXB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2537592284","title":"Press Release: Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2537592284","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537592284?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:10","pubTimestamp":1747944600,"startTime":"0","endTime":"0","summary":"Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry. Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020. NEW YORK and WALTHAM, Mass., May 22, 2025  -- Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company's Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experience. Dianthus also announced that Lonnie Moulder will transition from the Board of Directors.\"The Dianthus team has done an excellent job executing rapidly on its three clinical programs with DNTH103,\" said Dr. Read. \"This is an exciting time for the Company with Phase 2 MaGic results anticipated in September. I look forward to part","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4232","UK","BK4022","BK4205","LENZ","DNTH","R","BK4007","BK4528","BK4539","BK4233"],"gpt_icon":0},{"id":"2537924032","title":"Dianthus Therapeutics Inc. Appoints Simon Read, Ph.D., to Board as Leon O. Moulder, Jr. Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2537924032","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537924032?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:06","pubTimestamp":1747944406,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc. has announced a change in its Board of Directors. Leon O. Moulder, Jr. has resigned from the board, while Simon Read, Ph.D., has been appointed as a Class III director. Dr. Read will also serve as a member of the Science and Technology Committee and the Nominating and Corporate Governance Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLbQBWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2535678446","title":"Dianthus Therapeutics Inc: Phase 2 Momentum Trial of Dnth103 in Multifocal Motor Neuropathy Ongoing; Top-Line Results Anticipated in 2H'26","url":"https://stock-news.laohu8.com/highlight/detail?id=2535678446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535678446?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:35","pubTimestamp":1747082153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nFWN3RK2ER:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2535895687","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2535895687","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535895687?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:01","pubTimestamp":1747080060,"startTime":"0","endTime":"0","summary":"Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis . Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26. Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy  ongoing; interim responder analysis anticipated in 2H'26. Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy  ongoing;\"The first few months of 2025 represent continued excellence in execution by the Dianthus team, including the timely completion of enrollment in our Phase 2 MaGic trial of DNTH103 in gMG, and we look forward to reporting top-line results in September,\" said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. \"Despite currently approved biologics in the gMG market, significant opportunities remain for improved first-line treatment options. We believe that achieving DNTH103's target profile of effective, consistent symptom control, di","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","LU0971096721.USD","IE00BKVL7J92.USD","BK4539","CMC","LU0149725797.USD","BK4139","DNTH","IE00BHPRN162.USD","BK4006","IE00BZ1G4Q59.USD","LU0882574139.USD","LU0170899867.USD","BK4007","LU1363072403.SGD","LU0267386448.USD","LENZ"],"gpt_icon":0},{"id":"2533585311","title":"Dianthus Therapeutics Inc  expected to post a loss of 85 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2533585311","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533585311?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:46","pubTimestamp":1746445568,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc  expected to post a loss of85cents a share - Earnings Preview Dianthus Therapeutics Inc DNTH.OQ DNTH.O is expected to show a fall in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nL8N3RD0RD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH"],"gpt_icon":0},{"id":"2533300126","title":"Dianthus Therapeutics Completes Enrollment of Phase 2 Magic Trial of Dnth103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2533300126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533300126?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:00","pubTimestamp":1746442802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA3TZQWD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2533007743","title":"Dianthus Therapeutics Inc: Top-Line Results Anticipated This September","url":"https://stock-news.laohu8.com/highlight/detail?id=2533007743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533007743?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:00","pubTimestamp":1746442802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nTUA3TZQWD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2531786982","title":"Dianthus Therapeutics to Participate in Two Upcoming Investor Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786982","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531786982?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924400,"startTime":"0","endTime":"0","summary":"NEW YORK and WALTHAM, Mass., April 29, 2025  -- Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at two upcoming investor events.Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.Bank of America 2025 Health Care Conference – Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, May 14 at 5:35 p.m. EDT / 2:35 p.m. PDT and will host one-on-one meetings with investors.Webcasts of these presentations may be accessed under “News and Events” in the Investorssection of the Dianthus Therapeutics website.To learn more, please visit www.dianthustx.com and follow us on LinkedIn.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dianthus-therapeutics-participate-two-upcoming-110000069.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DNTH","BK4007","LENZ"],"gpt_icon":0},{"id":"2528018773","title":"Point72 Asset Management, L.p. Reports 5.9% Passive Stake in Dianthus Therapeutics as of April 10 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2528018773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528018773?lang=en_us&edition=fundamental","pubTime":"2025-04-18 04:22","pubTimestamp":1744921359,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nFWN3QV3EA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2522774924","title":"Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522774924","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522774924?lang=en_us&edition=fundamental","pubTime":"2025-03-24 21:57","pubTimestamp":1742824620,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals  shares soared 11.8% in the last trading session to close at $283.34. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% gain over the past four weeks.For Dianthus Therapeutics, Inc. , the consensus EPS estimate for the upcoming report has changed +5.3% over the past month to -$0.86. This represents a change of -59.3% from what the company reported a year ago. Dianthus Therapeutics, Inc. currently has a Zacks Rank of #3 .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alnylam-alny-surges-11-8-135700394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4139","ALNY","BK4548","DNTH","BK4585"],"gpt_icon":0},{"id":"2518085085","title":"Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2518085085","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518085085?lang=en_us&edition=fundamental","pubTime":"2025-03-12 09:35","pubTimestamp":1741743316,"startTime":"0","endTime":"0","summary":"Yaron Werber, an analyst from TD Cowen, has initiated a new Buy rating on Dianthus Therapeutics (DNTH). Yaron Werber’s rating is based on several c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-promising-growth-potential-with-innovative-dnth103-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dianthus-therapeutics-promising-growth-potential-with-innovative-dnth103-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DNTH","LENZ"],"gpt_icon":0},{"id":"2518677110","title":"Dianthus Therapeutics Inc: $357.0 Mln of Cash Provides Runway Into 2H'27","url":"https://stock-news.laohu8.com/highlight/detail?id=2518677110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518677110?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:13","pubTimestamp":1741723991,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU178:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2518577153","title":"Dianthus Therapeutics Inc - Q4 Shr Loss $0.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2518577153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518577153?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:06","pubTimestamp":1741723578,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU147:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DNTH"],"gpt_icon":0},{"id":"2518577903","title":"Dianthus Therapeutics Q4 EPS $(0.81) Beats $(0.85) Estimate, Sales $1.32M Beat $859.70K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518577903","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518577903?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:03","pubTimestamp":1741723408,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 14.08 percent decrease over losses of $(0.71) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44262066/dianthus-therapeutics-q4-eps-0-81-beats-0-85-estimate-sales-1-32m-beat-859-70k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","DNTH"],"gpt_icon":0},{"id":"2518779779","title":"Press Release: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2518779779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518779779?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:01","pubTimestamp":1741723260,"startTime":"0","endTime":"0","summary":"Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis  ongoing; top-line results on track for 2H'25. Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy  ongoing; interim responder analysis anticipated in 2H'26. Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy  ongoing;\"We remain on track to report top-line data in 2H'25 from our Phase 2 clinical trial of DNTH103 in gMG, an indication where a best-in-class, potent active C1s and classical pathway inhibitor with the potential for effective and consistent symptom control along with improved safety and convenience could meaningfully advance the standard of care,\" said Marino Garcia, Chief Executive Officer of Dianthus Therapeutics. \"We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP, which is on track for an interim responder analysis in 2H'26, along with top-line results from our Phase 2 trial in MMN.\". -- Phase 3 CAPTIVATE CIDP trial ongoing: The CAP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","BK4006","LU0170899867.USD","LU0149725797.USD","LU0267386448.USD","LU0882574139.USD","LU1363072403.SGD","CMC","IE00BZ1G4Q59.USD","DNTH","IE00BKVL7J92.USD","LENZ","IE00BHPRN162.USD","BK4139","LU0971096721.USD"],"gpt_icon":0},{"id":"2517136039","title":"Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, a Seasoned Commercial Leader, to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2517136039","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517136039?lang=en_us&edition=fundamental","pubTime":"2025-03-05 20:00","pubTimestamp":1741176001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nTUA8QXZY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139"],"gpt_icon":0},{"id":"2511301590","title":"Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511301590","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511301590?lang=en_us&edition=fundamental","pubTime":"2025-02-12 22:25","pubTimestamp":1739370300,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals  shares rallied 5.2% in the last trading session to close at $129.98. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.3% gain over the past four weeks.Rising optimism related to the company’s diverse portfolio of marketed drugs, including leading therapies for sleep disorders and epilepsy and a growing portfolio of cancer treatments, might have driven the recent share price rally.This drugmaker is expected to post quarterly earnings of $5.79 per share in its upcoming report, which represents a year-over-year change of +15.3%. Revenues are expected to be $1.06 billion, up 4.8% from the year-ago quarter.For Jazz, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on JAZZ going forward to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-jazz-surges-5-2-142500717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","LU0889565916.HKD","BK4139","BK4532","JAZZ","BK4007","DNTH","BK4533","LU0109394709.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BN0W2W23.USD"],"gpt_icon":0},{"id":"2510285112","title":"Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510285112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510285112?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:45","pubTimestamp":1739191543,"startTime":"0","endTime":"0","summary":"In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-dianthus-therapeutics-dnth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-dianthus-therapeutics-dnth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DNTH","SF"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DNTH\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"DNTH","fiscalQuarterEnding":"2025/03","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.82},{"market":"US","date":"2025-03-11","symbol":"DNTH","fiscalQuarterEnding":"2024/12","expectedEps":-0.85,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"DNTH","fiscalQuarterEnding":"2024/09","expectedEps":-0.59,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2024-08-08","symbol":"DNTH","fiscalQuarterEnding":"2024/06","expectedEps":-0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"post","actualEps":-0.51},{"market":"US","date":"2024-05-09","symbol":"DNTH","fiscalQuarterEnding":"2024/03","expectedEps":-0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":-0.54}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DNTH\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DNTH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":12,"updateTime":1734753600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DNTH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DNTH","date":"2025-06-06","current":-5.92871,"percent":0.782716,"low":-21.520733,"twenty":-15.126544,"median":-10.582949,"eighty":-5.698841,"high":-2.378652,"avg":-10.802067,"sd":4.641473,"marketCap":597210865},"quantilePoints":[{"date":"2023-09-22","current":-6.821887,"twenty":-6.869759,"median":-6.842701,"eighty":-6.807317,"marketCap":194260047},{"date":"2023-09-29","current":-5.576152,"twenty":-6.838538,"median":-5.576152,"eighty":-5.435929,"marketCap":201460812},{"date":"2023-10-06","current":-4.920135,"twenty":-6.800032,"median":-5.4757,"eighty":-5.354747,"marketCap":177759540},{"date":"2023-10-13","current":-4.916034,"twenty":-6.077097,"median":-5.403948,"eighty":-4.942276,"marketCap":177611407},{"date":"2023-10-20","current":-5.11694,"twenty":-5.587632,"median":-5.309646,"eighty":-5.016077,"marketCap":184869921},{"date":"2023-10-27","current":-4.75613,"twenty":-5.576152,"median":-5.262494,"eighty":-4.957036,"marketCap":171834222},{"date":"2023-11-03","current":-4.920135,"twenty":-5.49415,"median":-5.12514,"eighty":-4.920135,"marketCap":177759540},{"date":"2023-11-10","current":-4.678228,"twenty":-5.457249,"median":-5.084139,"eighty":-4.879133,"marketCap":169019695},{"date":"2023-11-17","current":-3.935775,"twenty":-5.444949,"median":-4.957036,"eighty":-4.76023,"marketCap":169663374},{"date":"2023-11-24","current":-4.021709,"twenty":-5.412148,"median":-4.920135,"eighty":-4.674948,"marketCap":173367815},{"date":"2023-12-01","current":-3.842966,"twenty":-5.377707,"median":-4.920135,"eighty":-3.993522,"marketCap":165662579},{"date":"2023-12-08","current":-3.640162,"twenty":-5.338346,"median":-4.907834,"eighty":-3.949524,"marketCap":156920099},{"date":"2023-12-15","current":-2.684576,"twenty":-5.297345,"median":-4.846332,"eighty":-3.884902,"marketCap":115726721},{"date":"2023-12-22","current":-3.007688,"twenty":-5.267824,"median":-4.788931,"eighty":-3.85534,"marketCap":129655417},{"date":"2023-12-29","current":-3.482043,"twenty":-5.235843,"median":-4.75818,"eighty":-3.842966,"marketCap":150103929},{"date":"2024-01-05","current":-4.482315,"twenty":-5.235843,"median":-4.715129,"eighty":-3.861528,"marketCap":193223616},{"date":"2024-01-12","current":-4.05952,"twenty":-5.169421,"median":-4.670027,"eighty":-3.873902,"marketCap":174997769},{"date":"2024-01-19","current":-3.952961,"twenty":-5.12186,"median":-4.521845,"eighty":-3.879402,"marketCap":170404263},{"date":"2024-01-26","current":-6.135656,"twenty":-5.267824,"median":-4.661827,"eighty":-3.893152,"marketCap":264495873},{"date":"2024-02-02","current":-14.091886,"twenty":-5.428549,"median":-4.735629,"eighty":-3.901401,"marketCap":607473021},{"date":"2024-02-09","current":-15.77856,"twenty":-5.593373,"median":-4.788931,"eighty":-3.913775,"marketCap":680182147},{"date":"2024-02-16","current":-16.247836,"twenty":-6.141843,"median":-4.875033,"eighty":-3.933712,"marketCap":700411702},{"date":"2024-02-23","current":-16.322648,"twenty":-6.585949,"median":-4.911934,"eighty":-3.935775,"marketCap":703636704},{"date":"2024-03-01","current":-16.832731,"twenty":-6.855189,"median":-4.920135,"eighty":-3.939212,"marketCap":725625351},{"date":"2024-03-08","current":-17.220393,"twenty":-14.108208,"median":-4.920135,"eighty":-3.952961,"marketCap":742336722},{"date":"2024-03-15","current":-18.274564,"twenty":-15.869694,"median":-5.055438,"eighty":-3.952961,"marketCap":787779926},{"date":"2024-03-22","current":-19.002283,"twenty":-16.27504,"median":-5.103895,"eighty":-3.958461,"marketCap":819150396},{"date":"2024-03-28","current":-20.617859,"twenty":-16.390659,"median":-5.12104,"eighty":-3.98046,"marketCap":898010856},{"date":"2024-04-05","current":-16.662734,"twenty":-16.662734,"median":-5.235843,"eighty":-3.987335,"marketCap":725745374},{"date":"2024-04-12","current":-16.777278,"twenty":-16.777278,"median":-5.350646,"eighty":-3.990772,"marketCap":730734324},{"date":"2024-04-19","current":-15.922581,"twenty":-16.832731,"median":-5.444949,"eighty":-3.99421,"marketCap":693508032},{"date":"2024-04-26","current":-14.143673,"twenty":-16.777278,"median":-5.535151,"eighty":-4.021709,"marketCap":616027659},{"date":"2024-05-03","current":-16.178636,"twenty":-16.662734,"median":-5.637242,"eighty":-4.021709,"marketCap":704660510},{"date":"2024-05-10","current":-14.570862,"twenty":-16.662734,"median":-6.140812,"eighty":-4.049207,"marketCap":731661246},{"date":"2024-05-17","current":-15.342363,"twenty":-16.621896,"median":-6.530951,"eighty":-4.05952,"marketCap":770401432},{"date":"2024-05-24","current":-12.724299,"twenty":-16.45867,"median":-6.737265,"eighty":-4.100768,"marketCap":638937940},{"date":"2024-05-31","current":-12.098897,"twenty":-16.404261,"median":-6.842701,"eighty":-4.106268,"marketCap":607534008},{"date":"2024-06-07","current":-12.233329,"twenty":-16.390659,"median":-12.098897,"eighty":-4.121392,"marketCap":614284386},{"date":"2024-06-14","current":-15.75779,"twenty":-16.354335,"median":-12.233329,"eighty":-4.176389,"marketCap":791261684},{"date":"2024-06-21","current":-15.114854,"twenty":-16.327131,"median":-12.630781,"eighty":-4.296009,"marketCap":758977268},{"date":"2024-06-28","current":-14.565435,"twenty":-16.324142,"median":-12.706764,"eighty":-4.381256,"marketCap":731388767},{"date":"2024-07-05","current":-15.459702,"twenty":-16.325636,"median":-12.794437,"eighty":-4.452753,"marketCap":776293455},{"date":"2024-07-12","current":-16.932611,"twenty":-16.417863,"median":-13.066224,"eighty":-4.47819,"marketCap":850254116},{"date":"2024-07-15","current":-16.920921,"twenty":-16.466954,"median":-13.180199,"eighty":-4.480252,"marketCap":849667127},{"date":"2024-08-02","current":-16.371502,"twenty":-16.45867,"median":-13.180199,"eighty":-4.482315,"marketCap":822078626},{"date":"2024-08-09","current":-13.845994,"twenty":-16.50009,"median":-13.738229,"eighty":-4.561374,"marketCap":784804801},{"date":"2024-08-16","current":-15.438194,"twenty":-16.45867,"median":-13.792112,"eighty":-4.661827,"marketCap":875052279},{"date":"2024-08-23","current":-14.304023,"twenty":-16.390659,"median":-14.112289,"eighty":-4.678228,"marketCap":810766318},{"date":"2024-08-30","current":-14.899592,"twenty":-16.390659,"median":-14.219338,"eighty":-4.715129,"marketCap":844523786},{"date":"2024-09-06","current":-14.490462,"twenty":-16.375333,"median":-14.311791,"eighty":-4.74793,"marketCap":821333873},{"date":"2024-09-13","current":-14.402421,"twenty":-16.338396,"median":-14.319559,"eighty":-4.75941,"marketCap":816343639},{"date":"2024-09-20","current":-14.552608,"twenty":-16.324142,"median":-14.311791,"eighty":-4.783191,"marketCap":824856392},{"date":"2024-09-27","current":-13.993291,"twenty":-16.306326,"median":-14.304023,"eighty":-4.815172,"marketCap":793153726},{"date":"2024-10-04","current":-14.221161,"twenty":-16.285922,"median":-14.291076,"eighty":-4.861093,"marketCap":806069627},{"date":"2024-10-11","current":-14.672555,"twenty":-16.269355,"median":-14.319559,"eighty":-4.877493,"marketCap":831655088},{"date":"2024-10-18","current":-14.522306,"twenty":-16.254626,"median":-14.311791,"eighty":-4.902094,"marketCap":823138846},{"date":"2024-10-25","current":-14.475677,"twenty":-16.248614,"median":-14.360865,"eighty":-4.914394,"marketCap":820495874},{"date":"2024-10-31","current":-14.486039,"twenty":-16.239675,"median":-14.366036,"eighty":-4.918495,"marketCap":821083201},{"date":"2024-11-08","current":-13.087312,"twenty":-16.213004,"median":-14.381745,"eighty":-4.920135,"marketCap":878053924},{"date":"2024-11-15","current":-11.244659,"twenty":-16.189942,"median":-14.360865,"eighty":-4.920135,"marketCap":754426637},{"date":"2024-11-22","current":-8.941908,"twenty":-16.180782,"median":-14.311791,"eighty":-4.920135,"marketCap":599930480},{"date":"2024-11-29","current":-10.582949,"twenty":-16.17095,"median":-14.273283,"eighty":-4.920135,"marketCap":710031190},{"date":"2024-12-06","current":-10.437372,"twenty":-16.142849,"median":-14.241876,"eighty":-4.934895,"marketCap":700264191},{"date":"2024-12-13","current":-10.36679,"twenty":-16.097823,"median":-14.188265,"eighty":-4.996397,"marketCap":695528677},{"date":"2024-12-20","current":-10.163866,"twenty":-16.05809,"median":-14.112289,"eighty":-5.061998,"marketCap":681914073},{"date":"2024-12-27","current":-10.14622,"twenty":-16.019613,"median":-14.091886,"eighty":-5.076759,"marketCap":680730195},{"date":"2025-01-03","current":-10.234448,"twenty":-15.922581,"median":-13.957579,"eighty":-5.096439,"marketCap":686649588},{"date":"2025-01-10","current":-11.284361,"twenty":-15.89482,"median":-13.822388,"eighty":-5.108369,"marketCap":757090364},{"date":"2025-01-17","current":-8.474299,"twenty":-15.887478,"median":-13.728741,"eighty":-5.115822,"marketCap":568557697},{"date":"2025-01-24","current":-9.828599,"twenty":-15.834329,"median":-13.708453,"eighty":-5.12186,"marketCap":659420380},{"date":"2025-01-31","current":-9.603618,"twenty":-15.788231,"median":-13.553088,"eighty":-5.191562,"marketCap":644325928},{"date":"2025-02-07","current":-10.128574,"twenty":-15.779567,"median":-13.462457,"eighty":-5.235843,"marketCap":679546316},{"date":"2025-02-14","current":-10.644708,"twenty":-15.766098,"median":-13.180199,"eighty":-5.267824,"marketCap":714174765},{"date":"2025-02-21","current":-10.455018,"twenty":-15.745542,"median":-13.087312,"eighty":-5.305545,"marketCap":701448070},{"date":"2025-02-28","current":-9.285997,"twenty":-15.702913,"median":-12.81575,"eighty":-5.346546,"marketCap":623016113},{"date":"2025-03-07","current":-10.375613,"twenty":-15.663831,"median":-12.724299,"eighty":-5.384267,"marketCap":696120616},{"date":"2025-03-14","current":-8.045567,"twenty":-15.60664,"median":-12.588406,"eighty":-5.420348,"marketCap":683623809},{"date":"2025-03-21","current":-7.727979,"twenty":-15.500032,"median":-12.233329,"eighty":-5.449869,"marketCap":656638658},{"date":"2025-03-28","current":-7.512473,"twenty":-15.459702,"median":-12.013661,"eighty":-5.472009,"marketCap":638327306},{"date":"2025-04-04","current":-6.416037,"twenty":-15.451099,"median":-11.624039,"eighty":-5.526951,"marketCap":545164287},{"date":"2025-04-11","current":-5.898066,"twenty":-15.431979,"median":-11.290978,"eighty":-5.587632,"marketCap":501152792},{"date":"2025-04-17","current":-7.175981,"twenty":-15.413286,"median":-11.262304,"eighty":-5.60754,"marketCap":609735897},{"date":"2025-04-25","current":-8.026663,"twenty":-15.369114,"median":-11.0285,"eighty":-5.622077,"marketCap":682017550},{"date":"2025-05-02","current":-8.204554,"twenty":-15.321347,"median":-10.898364,"eighty":-5.689407,"marketCap":697132746},{"date":"2025-05-09","current":-7.796217,"twenty":-15.230244,"median":-10.759405,"eighty":-5.898822,"marketCap":662436738},{"date":"2025-05-16","current":-5.986178,"twenty":-15.201008,"median":-10.704262,"eighty":-5.916298,"marketCap":602999662},{"date":"2025-05-23","current":-5.861665,"twenty":-15.193619,"median":-10.675588,"eighty":-5.916298,"marketCap":590457269},{"date":"2025-05-30","current":-5.698841,"twenty":-15.181369,"median":-10.600594,"eighty":-5.861665,"marketCap":574055678},{"date":"2025-06-06","current":-5.92871,"twenty":-15.126544,"median":-10.582949,"eighty":-5.698841,"marketCap":597210865}],"updateTime":1749294886297}}}